Transient osteoporosis of the hip: successful treatment with teriparatide

Fabbriciani, Gianluigi; Pirro, Matteo; Manfredelli, Maria Rosaria; Bianchi, Massimo; Sivolella, Silvio; Scarponi, Anna Maria

doi:10.1007/s00296-010-1404-7

Cited by 26 publications

(14 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In another study, the BMe was resolved on MRI at 6 months in the 8 cases studied [42]. teriparatide, a treatment for osteoporosis, has also been shown to resolve BMeSH 1 month after treatment [43].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of extracorporeal shock wave therapy in bone marrow edema syndrome of the hip

et al. 2014

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Effectiveness of extracorporeal shock wave therapy in bone marrow edema syndrome of the hip

et al. 2014

View full text Add to dashboard Cite

“…We therefore recommend excluding HPP by measuring ALP activity and PLP in cases of borderline values in all patients that are treated with an antiresorptive drug for BME. Although the osteoanabolic drug, teriparatide was shown to reduce bone edema in one single case of a patient with BME at the hip and showed good clinical improvement in our case 1, this should be only considered in adult HPP patients with persistent BME. In pediatric patients, treatment with teriparatide is generally not recommended because the development of osteosarcoma during the rapid phase of longitudinal skeletal growth has been found in rats .…”

Section: Discussionmentioning

confidence: 66%

Outcome of Teriparatide Treatment on Fracture Healing Complications and Symptomatic Bone Marrow Edema in Four Adult Patients With Hypophosphatasia

et al. 2019

View full text Add to dashboard Cite

The response to teriparatide has been described in very few cases of hypophosphatasia (HPP). In this cross‐sectional study, we report the prevalence of symptomatic bone marrow edema (BME) and fracture healing complications in a large cohort of childhood and adult HPP patients and discuss the results of teriparatide treatment in four cases. From 2016 to 2018, 51 patients with a diagnosis of HPP were seen at our institution. The diagnosis of HPP was established by low serum alkaline phosphatase (ALP), elevated serum pyridoxal‐5‐phosphate (PLP), at least one typical clinical symptom of HPP and supported by ALPL mutation analysis. In this study cohort, 28 (56%) and 14 (27%) patients had a history of fracture or a history of BME, respectively. Four patients, including middle‐aged to elderly women and men who all presented with persistent symptomatic BME or fracture healing complications, were treated with teriparatide. DXA was performed prior to treatment and laboratory values were measured on a regular basis during treatment. Treatment with teriparatide showed variable effects in terms of clinical and biochemical response. Although all four patients displayed a temporary increase in ALP activity, only two patients with a mild form of adult HPP and moderately increased PLP levels showed definite clinical and radiological improvement after teriparatide treatment. In conclusion, fracture healing complications and BME occur frequently in HPP patients. Teriparatide shows variable clinical and biochemical effects depending on the severity of the disease. PLP levels and the number of ALPL alleles might be good parameters to predict treatment outcomes. © 2019 The Authors. JBMR Plus Published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research

show abstract

“…Tedaviye en hızlı cevap zoledronik asit ve teriparatid tedavisi ile, olgu sunumu olarak bildirilmiştir. Kalça tutulumu olan, GBO tanısı konulan bir hastada zoledronik asit tedavisi sonrası 4 haftada klinik iyileşme, 6 ayda radyolojik iyileşme (26), yine kalça tutulumu olan GBO tanısı konulan ve teriparatid tedavisi verilen bir hastada ise 4 haftadan sonra semptomların tamamen geçtiği 2 ay sonra ise radyolojik düzelme olduğu bildirilmiştir (27). Yapılan bir çalışmada zoledronik asit 5 mg tek doz uygulanan, GBO tanısı konulmuş 17 hastanın 15'inde 3 ay sonunda semptomların gerilediği hatta tamamen geçtiği bildirilmiştir (25).…”

Section: Olgu Sunumuunclassified

Regional Migratory Osteoporosis: A Case Report

Atici¹,

Akpinar²,

Özkan³

et al. 2018

Tod

View full text Add to dashboard Cite

Regional migratory osteoporosis is characterized by migratory transient regional osteoporosis attacks. The etiology is not explained completely. Although it is a self-limiting benign disease, it causes serious arthralgia in involved joint and loss of labor force. It is important to make the differential diagnosis with many diseases which causes bone marrow edema. Therefore, herein we present a fifty-four-year old male patient diagnosed with regional migratory osteoporosis of the hip, knee, and ankle involvement.

show abstract

Transient osteoporosis of the hip: successful treatment with teriparatide

Cited by 26 publications

References 16 publications

Effectiveness of extracorporeal shock wave therapy in bone marrow edema syndrome of the hip

Effectiveness of extracorporeal shock wave therapy in bone marrow edema syndrome of the hip

Outcome of Teriparatide Treatment on Fracture Healing Complications and Symptomatic Bone Marrow Edema in Four Adult Patients With Hypophosphatasia

Regional Migratory Osteoporosis: A Case Report

Contact Info

Product

Resources

About